Men's Health News

RSS

University of Michigan offers new test to improve PSA screening for prostate cancer

More than 1 million men will undergo a prostate biopsy this year, but only about one-fifth of those biopsies will result in a cancer diagnosis.

26 Sep 2013

Drug to treat metastatic castration-resistant prostate cancer delays progression of pain and quality of life deterioration in men

Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone.

25 Sep 2013

Guideline focuses on radiation therapy to be highlighted during ASTRO's 55th Annual Meeting

The American Society for Radiation Oncology will highlight the recently published Adjuvant and Salvage Radiotherapy After Prostatectomy: ASTRO/AUA Guideline during ASTRO's 55th Annual Meeting, September 22-25, 2013, in Atlanta.

24 Sep 2013

Long-term hormonal therapy has no additional benefits in men with intermediate-risk prostate cancer

A secondary analysis of the historic RTOG 9202 prostate cancer trial examined results of men with intermediate-risk prostate cancer who had received long-term hormonal therapy after radiation therapy, and concluded that there were no additional benefits when compared to short-term hormonal therapy, according to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting.

24 Sep 2013

Boys’ chronic aggressive behavior may be due to epigenetic changes during pregnancy, early childhood

Chronic aggressive behaviour exhibited by some boys from disadvantaged families may be due to epigenetic changes during pregnancy and early childhood.

23 Sep 2013

CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use recommended Xofigo (radium Ra 223 dichloride) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

20 Sep 2013

Clinical trial by Moffitt to reduce risk of prostate cancer in black men

Prostate cancer kills more African-American and black men than any other group. Yet, according to a new review published by Moffitt Cancer Center researchers, there is a significant lack of clear and consistent screening and early detection guidelines or prevention strategies.

20 Sep 2013

Postpartum sexuality: an interview with Dr Sari van Anders, University of Michigan, Ann Arbor

Research on postpartum seems to have focused on birth mothers for good reason: women (and, of course, some transmen) are the ones who carry a pregnancy and give birth, and the postpartum is conceptualized as “following birth”.

19 Sep 2013

Only few service providers are available to help young gay black men, say researchers

Physical, sexual and emotional abuse among young gay black men is a pervasive problem, yet there remains a lack of social services and resources available to help them, a Michigan State University scholar argues in a new study.

19 Sep 2013

Obese men who binge are more likely to have elevated cholesterol, high blood pressure

Binge eating is a problem affecting both men and women, however obese men who binge are more likely than their female counterparts to have elevated cholesterol and high blood pressure, finds a new study in General Hospital Psychiatry.

18 Sep 2013

ISA Pharmaceuticals announces initiation of ISA101 Phase I/II trial in HIV-positive men with AIN

ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections, today announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in HIV-positive men suffering from anal intraepithelial neoplasia.

16 Sep 2013

Three-gene biomarker can help determine treatment option for early prostate cancer

The level of expression of three genes associated with aging can be used to predict whether seemingly low-risk prostate cancer will remain slow-growing, according to researchers at the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center.

13 Sep 2013

Metamark reports positive results from clinical validation study of prostate cancer prognostic test

Metamark Genetics, Inc., a privately-held biotechnology company, today announced positive results from a large clinical validation study of ProMark, its biopsy-based prostate cancer prognostic test.

10 Sep 2013

Roche, Inovio Pharmaceuticals to develop DNA-based vaccines for prostate cancer and hepatitis B

Roche and Inovio Pharmaceuticals, Inc. announced today that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B.

10 Sep 2013

Greenwich Hospital's new radiation oncology therapy gives renewed hope to HRPC patients

At the end of July, Greenwich became the only hospital in New York City, Westchester and Fairfield counties to offer Xofigo, commonly referred to as Radium 223, a new radiation oncology therapy that is giving renewed hope to patients with stage 4 hormone-refractory prostate cancer.

6 Sep 2013

Endo Pharmaceuticals' complete response submission to AVEED NDA accepted by FDA

Endo Pharmaceuticals Inc., a subsidiary of Endo Health Solutions Inc. announced today that the U.S. Food and Drug Administration has accepted for review the complete response submission made by Endo to the new drug application for its long-acting testosterone undecanoate injection, AVEED, intended for men diagnosed with hypogonadism.

6 Sep 2013

$Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma$

Pivotal Study Supports Use of IMNOVID®▼ Pomalidomide in Patients with Relapsed or Refractory Multiple Myeloma

The Lancet Oncology published this week findings from a study, which showed that the new oral therapy IMNOVID®▼ (pomalidomide), used in combination with low-dose dexamethasone demonstrated a significant survival advantage over high-dose dexamethasone alone, in patients with relapsed and refractory multiple myeloma (rrMM).1

5 Sep 2013

Research: Men who exercise vigorously may reduce risk of epilepsy later in life

New research suggests that men who exercise vigorously as young adults may reduce their risk of developing epilepsy later in life. The study is published in the September 4, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology. Epilepsy is a brain disease that causes repeated seizures over time.

5 Sep 2013

Study of older men shows that stressful life events increase risk of falls

A study of around 5,000 older men has shown that stressful life events such as death of a loved one, or serious financial problems, significantly raised the risk of falls in the year following the incident. The research is published online today in the journal Age and Ageing.

4 Sep 2013

Leisure-time physical activity might reduce risk of SCD among men with low CRF

Dr Laukkanen said: "Sudden cardiac death (SCD) accounts for approximately 50% of deaths from coronary heart disease. SCD typically occurs shortly after the onset of symptoms, leaving little time for effective medical interventions, and most cases occur outside hospital with few or no early warning signs. Finding ways to identify individuals at elevated risk of SCD would allow early interventions on risk factors to be implemented."

2 Sep 2013